For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Nootropic & Cognitive · Comparison

Colostrinin vs Dihexa

A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

ColostrininDihexa
CategoryNootropic & CognitiveNootropic & Cognitive
Also known asPRP (proline-rich polypeptide), ND, colostrum neuropeptide, CLN, ovine proline-rich polypeptidePNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
EvidenceResearch-stagePreclinical only
Dosing range100mcg–400mcg mcg, sublingual, on a 3 days on / 3 days off cycle10mg–20mg mg, Once daily (or every other day — long-lasting effects)
AdministrationSublingual tablet/dropOral (capsule), Transdermal (cream/lotion — lipophilicity makes this effective), Subcutaneous injection (less common)
Key side effectsGenerally well-tolerated, Mild GI discomfort, Rare hypersensitivity (relevant for dairy protein sensitivity), Mild fatigue (initial days)Potential for pro-proliferative effects — HGF/c-Met pathway promotes cell growth (theoretical cancer concern at high doses), Headache (uncommon), Mental fatigue if overdosed, Long half-life means effects accumulate — take every other day initially
Cited sources2 references2 references

Key differences

  • Evidence level differs: Colostrinin is research-stage, while Dihexa is preclinical only.
  • Administration: Colostrinin — Sublingual tablet/drop; Dihexa — Oral (capsule), Transdermal (cream/lotion — lipophilicity makes this effective), Subcutaneous injection (less common).
  • Dosing units differ: Colostrinin is dosed in mcg, Dihexa in mg — they operate at different scales.
  • Frequency: Colostrinin is typically sublingual, on a 3 days on / 3 days off cycle; Dihexa is Once daily (or every other day — long-lasting effects).

How each works

Colostrinin

Colostrinin modulates dendritic cell maturation and shifts cytokine balance toward anti-inflammatory patterns (reduced IL-6, TNF-α; increased IL-10). In neurological models, it reduces amyloid-β aggregation, decreases oxidative stress, and upregulates NGF while modulating the HPA axis stress response. A Polish double-blind trial showed statistically significant cognitive stabilization in mild-to-moderate AD patients over 15 weeks.

Dihexa

Dihexa (PNB-0408) was developed by Joseph Harding and colleagues at WSU as a metabolically stable angiotensin IV analog. It binds hepatocyte growth factor (HGF), potentiating its interaction with the c-Met receptor — a pathway critical for dendritic branching, synapse formation, and synaptic plasticity. In rodent Alzheimer's and scopolamine-impaired models, Dihexa restored cognitive performance at doses ~7 orders of magnitude lower than BDNF. It readily crosses the blood-brain barrier due to its lipophilicity, unlike BDNF itself.

Read the full Colostrinin profileRead the full Dihexa profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.